Laurent GREILLIER
Groupe Français de Pneumo-Cancérologie (GFPC) · AP-HM / Groupe Français d'Onco-Pneumologie · Hopital Nord, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Laurent GREILLIER as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:36 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06646471 · PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic MalignanciesGFPC Investigation · recruiting · Non Small Cell Lung Cancer, Lung Cancer · study chair
- Ph2NCT06552234 · Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCCentre Hospitalier Intercommunal de Toulon La Seyne sur Mer · recruiting · NSCLC Stage IV, NSCLC, Stage III · study director
- Ph2/Ph3NCT02784171 · Pembrolizumab in Patients With Advanced Malignant Pleural MesotheliomaCanadian Cancer Trials Group · completed · Mesothelioma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:36 UTC. The ranking covers the 200 most relevant of 48 PubMed records, and a shared surname and initials can bring in a namesake. All 48 on PubMed
- 1,015 citationsRCR 56.5
- 762 citationsRCR 25.8
- 368 citationsRCR 13.3
- 304 citationsRCR 10.4
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.Clin Cancer Res · 2019280 citationsRCR 9.8
- Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.J Thorac Oncol · 2021264 citationsRCR 13.5
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.J Clin Oncol · 2021254 citationsRCR 12.1
- 248 citationsRCR 15.0
- 152 citationsRCR 4.6
- 145 citationsRCR 14.7